All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Which factors help guide therapy choice for relapsed/refractory (R/R) diffuse large B-cell lymphoma?
Which factors help guide therapy choice for R/R diffuse large B-cell lymphoma?
In this video, Salles discusses insights presented during EHA2021 regarding the selection of patients with R/R diffuse large B-cell lymphoma for second-line therapy. Although autologous hematopoietic stem cell transplant (auto-HSCT) remains the standard of care, a recent randomized study is comparing auto-HSCT with chimeric antigen receptor (CAR) T-cell therapy. Salles also points out that the antibody-drug conjugate loncastuximab tesirine could be a feasible approach prior to treatment with CAR T-cell therapy.
How will CAR T therapy for lymphoma be used in the future?
Gilles Salles explains that the use of CAR T cells will expand in the future, as the current market approval is for patients in the third line of therapy with primary mediastinal B‐cell...
What factors should be considered when choosing between novel treatment options for R/R DLBCL?
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Kami J Maddocks, The Ohio State University, Columbus, US. We asked, What factors should be...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox